

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2016**

**Commission File Number 001-36866**

---

**SUMMIT THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

**85b Park Drive  
Milton Park, Abingdon  
Oxfordshire OX14 4RY  
United Kingdom  
(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F       FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES       NO

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

---

On June 24, 2016, Summit Therapeutics plc (the “Company”) issued a press release announcing that it had granted share options to certain officers and employees of the Company under its 2016 Long Term Incentive Plan. The related press release is attached hereto as Exhibit 99.1.

The information in this Report on Form 6-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SUMMIT THERAPEUTICS PLC

By: /s/ Erik Ostrowski  
Erik Ostrowski  
Chief Financial Officer

Date: June 24, 2016

---

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description**

---

99.1

Press release dated June 24, 2016



**Summit Therapeutics plc**  
 (“Summit” or the “Company”)

**AWARD OF SHARE OPTIONS**

**Oxford, UK, 24 June 2016** – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and *C. difficile* infection, announces that on 23 June 2016 it granted share options over 250,000 new ordinary shares of 1p nominal value (“Shares”) at an exercise price of 105.0 pence per Share to the Company’s Chief Financial Officer, Erik Ostrowski. These options will vest in full on 23 June 2019 subject to achievement of performance conditions pertaining to certain corporate and programme development milestones. These options will lapse in full if the performance conditions are not met by 23 June 2019.

The Company has also granted share options over 1,307,000 new Shares at an exercise price of 105.0 pence per Share to other employees of the Company. These options will vest in nine equal tranches on a quarterly basis from 23 June 2017 and will vest in full on 23 June 2019.

The above exercise price is the mid-market closing price of Summit’s Shares on 23 June 2016.

The Company’s Chief Executive Officer, Glyn Edwards, has also been granted nominal-cost share options over 110,576 new Shares. As detailed in the Directors’ Remuneration Report in the Company’s Annual Report and Accounts for 2015/16, this option grant is part the bonus awarded to Mr Edwards in recognition of achievement of Company performance objectives during the year ended 31 January 2016. Prior to the assessment of the bonus, the Remuneration Committee agreed with Mr Edwards for the bonus to be equally split between a cash payment (paid in February 2016) and a future grant of nominal cost share options. These options are subject to no further performance conditions and will become exercisable from 21 July 2016.

Each of these option awards have been made under the Company’s 2016 Long Term Incentive Plan.

- END -

**For more information, please contact:**

**Summit Therapeutics**

Richard Pye (UK office)  
 Erik Ostrowski (US office)

Tel: +44 (0)1235 443 951  
 +1 617 294 6607

**Cairn Financial Advisers LLP**

(Nominated Adviser)  
 Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7148 7900